Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02480439 · ClinicalTrials.gov registry record · Phase 1
A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants
A Phase 1 study, sponsored by Takeda.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02480439 is a Phase 1 study that has completed, run by Takeda. The registered enrollment target is 24 participants.
The verdict
NCT02480439, a Phase 1 study, has completed, sponsored by Takeda.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the relative bioavailability of a TAK-648 tablet compared with a TAK-648 oral solution, and to assess the effect of food on the bioavailability of a TAK-648 tablet in healthy participants.
Interventions
- DRUG TAK-648 Tablet
- DRUG TAK-648 Oral Solution
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-06 |
| Est. Completion | 2015-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02480439
The ClinicalTrials.gov registry entry for NCT02480439 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Takeda, which has 408 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which TAK-648 Tablet is the first listed.
NCT02480439 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02480439 about?
NCT02480439 is a clinical study titled "A Study to Assess the Relative Bioavailability and to Assess the Effect of Food on the Bioavailability of a TAK-648 Tablet in Healthy Participants". The purpose of this study is to assess the relative bioavailability of a TAK-648 tablet compared with a TAK-648 oral solution, and to assess the effect of food on the bioavailability of a TAK-648 tablet in healthy participants.
What is the current status of trial NCT02480439?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-06. Estimated completion is 2015-09.
What interventions are being tested in trial NCT02480439?
The interventions under investigation include: TAK-648 Tablet (DRUG), TAK-648 Oral Solution (DRUG).
Who is sponsoring clinical trial NCT02480439?
This trial is sponsored by Takeda, which has 408 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.